CLINICAL PARAMETERS

PLAQUE INDEX

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 31 | 0.52 | 0.51 | 0.49 |
| 2 | 40 | 0.26 | 0.24 | 0.23 |
| 3 | 14 | 0.54 | 0.54 | 0.52 |
| 4 | 41 | 0.66 | 0.65 | 0.62 |
| 5 | 6 | 0.32 | 0.3 | 0.28 |
| 6 | 37 | 0.21 | 0.18 | 0.16 |
| 7 | 29 | 0.42 | 0.41 | 0.37 |
| 8 | 34 | 0.51 | 0.49 | 0.46 |
| 9 | 44 | 0.24 | 0.23 | 0.21 |
| 10 | 3 | 0.21 | 0.21 | 0.18 |
| 11 | 20 | 0.59 | 0.58 | 0.56 |
| 12 | 22 | 0.85 | 0.82 | 0.74 |
| 13 | 13 | 0.68 | 0.67 | 0.64 |
| 14 | 25 | 0.62 | 0.62 | 0.58 |
| 15 | 10 | 0.57 | 0.56 | 0.54 |

Test group I: Treated with Open Flap Debridement (OFD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 38 | 0.65 | 0.64 | 0.63 |
| 2 | 24 | 0.84 | 0.83 | 0.8 |
| 3 | 4 | 0.26 | 0.24 | 0.2 |
| 4 | 19 | 0.8 | 0.79 | 0.78 |
| 5 | 35 | 0.3 | 0.27 | 0.25 |
| 6 | 1 | 0.45 | 0.43 | 0.42 |
| 7 | 28 | 0.45 | 0.45 | 0.43 |
| 8 | 15 | 0.72 | 0.71 | 0.68 |
| 9 | 21 | 0.56 | 0.56 | 0.54 |
| 10 | 9 | 0.75 | 0.74 | 0.72 |
| 11 | 11 | 0.69 | 0.68 | 0.67 |
| 12 | 30 | 0.38 | 0.38 | 0.36 |
| 13 | 27 | 0.35 | 0.34 | 0.32 |
| 14 | 17 | 0.52 | 0.51 | 0.49 |
| 15 | 43 | 0.56 | 0.54 | 0.52 |

Test group II: Treated with Open Flap Debridement (OFD) + EDTA + Enamel matrix derivative (EMD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 23 | 0.68 | 0.67 | 0.64 |
| 2 | 33 | 0.54 | 0.54 | 0.52 |
| 3 | 42 | 0.51 | 0.49 | 0.47 |
| 4 | 2 | 0.24 | 0.23 | 0.21 |
| 5 | 39 | 0.34 | 0.34 | 0.32 |
| 6 | 16 | 0.45 | 0.43 | 0.4 |
| 7 | 5 | 0.67 | 0.65 | 0.63 |
| 8 | 45 | 0.42 | 0.41 | 0.39 |
| 9 | 8 | 0.4 | 0.38 | 0.36 |
| 10 | 32 | 0.29 | 0.29 | 0.27 |
| 11 | 12 | 0.59 | 0.57 | 0.56 |
| 12 | 36 | 0.45 | 0.45 | 0.43 |
| 13 | 26 | 0.52 | 0.51 | 0.48 |
| 14 | 18 | 0.54 | 0.53 | 0.51 |
| 15 | 7 | 0.6 | 0.59 | 0.57 |

GINGIVAL INDEX

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 31 | 0.65 | 0.63 | 0.62 |
| 2 | 40 | 0.49 | 0.53 | 0.52 |
| 3 | 14 | 0.61 | 0.63 | 0.63 |
| 4 | 41 | 0.76 | 0.82 | 0.8 |
| 5 | 6 | 0.47 | 0.49 | 0.49 |
| 6 | 37 | 0.86 | 0.91 | 0.89 |
| 7 | 29 | 0.43 | 0.45 | 0.45 |
| 8 | 34 | 0.39 | 0.45 | 0.42 |
| 9 | 44 | 0.49 | 0.52 | 0.52 |
| 10 | 3 | 0.78 | 0.82 | 0.82 |
| 11 | 20 | 0.63 | 0.67 | 0.65 |
| 12 | 22 | 0.57 | 0.59 | 0.58 |
| 13 | 13 | 0.85 | 0.91 | 0.89 |
| 14 | 25 | 0.72 | 0.73 | 0.73 |
| 15 | 10 | 0.64 | 0.67 | 0.67 |

Test group I: Treated with Open Flap Debridement (OFD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 38 | 0.43 | 0.39 | 0.37 |
| 2 | 24 | 0.56 | 0.45 | 0.42 |
| 3 | 4 | 0.68 | 0.63 | 0.6 |
| 4 | 19 | 0.47 | 0.38 | 0.37 |
| 5 | 35 | 0.74 | 0.67 | 0.62 |
| 6 | 1 | 0.46 | 0.4 | 0.38 |
| 7 | 28 | 0.7 | 0.62 | 0.62 |
| 8 | 15 | 0.67 | 0.59 | 0.56 |
| 9 | 21 | 0.49 | 0.43 | 0.43 |
| 10 | 9 | 0.86 | 0.75 | 0.73 |
| 11 | 11 | 0.72 | 0.67 | 0.66 |
| 12 | 30 | 0.69 | 0.6 | 0.6 |
| 13 | 27 | 0.54 | 0.49 | 0.47 |
| 14 | 17 | 0.73 | 0.67 | 0.64 |
| 15 | 43 | 0.53 | 0.53 | 0.48 |

Test group II: Treated with Open Flap Debridement (OFD) + EDTA + Enamel matrix derivative (EMD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 23 | 0.53 | 0.41 | 0.41 |
| 2 | 33 | 0.8 | 0.69 | 0.69 |
| 3 | 42 | 0.78 | 0.57 | 0.56 |
| 4 | 2 | 0.37 | 0.32 | 0.29 |
| 5 | 39 | 0.25 | 0.21 | 0.21 |
| 6 | 16 | 0.51 | 0.45 | 0.43 |
| 7 | 5 | 0.83 | 0.76 | 0.73 |
| 8 | 45 | 0.47 | 0.38 | 0.38 |
| 9 | 8 | 0.54 | 0.51 | 0.47 |
| 10 | 32 | 0.42 | 0.34 | 0.34 |
| 11 | 12 | 0.72 | 0.66 | 0.63 |
| 12 | 36 | 0.76 | 0.62 | 0.62 |
| 13 | 26 | 0.52 | 0.43 | 0.41 |
| 14 | 18 | 0.63 | 0.56 | 0.54 |
| 15 | 7 | 0.68 | 0.62 | 0.58 |

PROBING POCKET DEPTH

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 31 | 8 | 6 | 6 |
| 2 | 40 | 7 | 4 | 5 |
| 3 | 14 | 8 | 5 | 4 |
| 4 | 41 | 9 | 7 | 6 |
| 5 | 6 | 7 | 5 | 5 |
| 6 | 37 | 7 | 5 | 6 |
| 7 | 29 | 9 | 7 | 7 |
| 8 | 34 | 8 | 7 | 6 |
| 9 | 44 | 8 | 6 | 6 |
| 10 | 3 | 7 | 6 | 5 |
| 11 | 20 | 8 | 6 | 6 |
| 12 | 22 | 9 | 7 | 8 |
| 13 | 13 | 7 | 6 | 6 |
| 14 | 25 | 9 | 6 | 5 |
| 15 | 10 | 8 | 5 | 5 |

Test group I: Treated with Open Flap Debridement (OFD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 38 | 7 | 5 | 5 |
| 2 | 24 | 8 | 6 | 6 |
| 3 | 4 | 7 | 5 | 4 |
| 4 | 19 | 8 | 5 | 5 |
| 5 | 35 | 9 | 6 | 7 |
| 6 | 1 | 8 | 6 | 6 |
| 7 | 28 | 8 | 7 | 6 |
| 8 | 15 | 10 | 8 | 7 |
| 9 | 21 | 9 | 7 | 6 |
| 10 | 9 | 7 | 5 | 5 |
| 11 | 11 | 7 | 4 | 5 |
| 12 | 30 | 8 | 6 | 6 |
| 13 | 27 | 9 | 7 | 7 |
| 14 | 17 | 7 | 5 | 5 |
| 15 | 43 | 8 | 5 | 6 |

Test group II: Treated with Open Flap Debridement (OFD) + EDTA + Enamel matrix derivative (EMD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 23 | 9 | 6 | 5 |
| 2 | 33 | 8 | 5 | 5 |
| 3 | 42 | 9 | 7 | 8 |
| 4 | 2 | 7 | 4 | 4 |
| 5 | 39 | 7 | 6 | 6 |
| 6 | 16 | 8 | 6 | 7 |
| 7 | 5 | 10 | 7 | 8 |
| 8 | 45 | 8 | 6 | 6 |
| 9 | 8 | 9 | 5 | 6 |
| 10 | 32 | 7 | 5 | 5 |
| 11 | 12 | 8 | 4 | 5 |
| 12 | 36 | 7 | 4 | 4 |
| 13 | 26 | 9 | 7 | 7 |
| 14 | 18 | 8 | 6 | 6 |
| 15 | 7 | 10 | 7 | 7 |

CLINICAL ATTACHMENT LEVEL

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 31 | 9 | 7 | 7 |
| 2 | 40 | 9 | 6 | 7 |
| 3 | 14 | 10 | 7 | 6 |
| 4 | 41 | 9 | 7 | 6 |
| 5 | 6 | 8 | 6 | 6 |
| 6 | 37 | 8 | 6 | 7 |
| 7 | 29 | 9 | 7 | 7 |
| 8 | 34 | 9 | 8 | 7 |
| 9 | 44 | 8 | 6 | 6 |
| 10 | 3 | 9 | 8 | 7 |
| 11 | 20 | 9 | 7 | 7 |
| 12 | 22 | 10 | 8 | 9 |
| 13 | 13 | 9 | 8 | 8 |
| 14 | 25 | 10 | 7 | 6 |
| 15 | 10 | 9 | 6 | 6 |

Test group I: Treated with Open Flap Debridement (OFD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 38 | 8 | 6 | 6 |
| 2 | 24 | 9 | 7 | 7 |
| 3 | 4 | 8 | 6 | 5 |
| 4 | 19 | 8 | 5 | 5 |
| 5 | 35 | 10 | 7 | 8 |
| 6 | 1 | 9 | 7 | 7 |
| 7 | 28 | 9 | 8 | 7 |
| 8 | 15 | 10 | 8 | 7 |
| 9 | 21 | 10 | 8 | 7 |
| 10 | 9 | 9 | 7 | 7 |
| 11 | 11 | 8 | 5 | 6 |
| 12 | 30 | 9 | 7 | 7 |
| 13 | 27 | 10 | 8 | 8 |
| 14 | 17 | 8 | 6 | 6 |
| 15 | 43 | 8 | 5 | 6 |

Test group II: Treated with Open Flap Debridement (OFD) + EDTA + Enamel matrix derivative (EMD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 3 MONTHS | 6 MONTHS |
|---------|---------------|----------|----------|----------|
| NUMBER | SERIAL NO. | | | |
| 1 | 23 | 9 | 6 | 5 |
| 2 | 33 | 9 | 6 | 6 |
| 3 | 42 | 10 | 8 | 7 |
| 4 | 2 | 9 | 6 | 6 |
| 5 | 39 | 9 | 8 | 8 |
| 6 | 16 | 9 | 7 | 8 |
| 7 | 5 | 10 | 7 | 8 |
| 8 | 45 | 8 | 6 | 6 |
| 9 | 8 | 9 | 5 | 6 |
| 10 | 32 | 8 | 6 | 6 |
| 11 | 12 | 9 | 5 | 6 |
| 12 | 36 | 9 | 6 | 6 |
| 13 | 26 | 9 | 7 | 7 |
| 14 | 18 | 9 | 7 | 7 |
| 15 | 7 | 10 | 7 | 7 |

DEFECT OF VERTICAL DEFECT AND PERCENTAGE BONE FILL

| PATIENT | RANDOMIZATION | BASELINE | 6 MONTHS | PERCENTAGE |
|---------|---------------|----------|----------|------------|
| NUMBER | SERIAL NO. | | | BONE FILL |
| 1 | 31 | 3.82 | 3.24 | 25.89 |
| 2 | 40 | 3.65 | 3.04 | 20.06 |
| 3 | 14 | 4.12 | 3.83 | 7.57 |
| 4 | 41 | 3.26 | 2.92 | 11.64 |
| 5 | 6 | 3.91 | 3.54 | 14.56 |
| 6 | 37 | 3.14 | 2.96 | 6.08 |
| 7 | 29 | 3.54 | 3.13 | 13.09 |
| 8 | 34 | 3.93 | 3.61 | 12.26 |
| 9 | 44 | 3.65 | 3.45 | 8.16 |
| 10 | 3 | 3.36 | 2.97 | 13.13 |
| 11 | 20 | 3.44 | 3.21 | 10.4 |
| 12 | 22 | 3.96 | 3.65 | 8.49 |
| 13 | 13 | 3.72 | 3.14 | 15.35 |
| 14 | 25 | 3.81 | 3.32 | 14.75 |
| 15 | 10 | 3.65 | 3.47 | 5.18 |

Test group I: Treated with Open Flap Debridement (OFD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 6 MONTHS | PERCENTAGE |
|---------|---------------|----------|----------|------------|
| NUMBER | SERIAL NO. | | | BONE FILL |
| 1 | 38 | 3.18 | 2.42 | 31.4 |
| 2 | 24 | 3.43 | 2.51 | 36.65 |
| 3 | 4 | 3.74 | 2.93 | 41.96 |
| 4 | 19 | 3.92 | 3.24 | 30.35 |
| 5 | 35 | 3.54 | 2.73 | 29.67 |
| 6 | 1 | 5.24 | 4.31 | 40.25 |
| 7 | 28 | 3.92 | 3.34 | 24.78 |
| 8 | 15 | 4.25 | 3.39 | 25.36 |
| 9 | 21 | 6.91 | 6.23 | 21.05 |
| 10 | 9 | 3.84 | 3.38 | 19.32 |
| 11 | 11 | 8.28 | 7.41 | 31.81 |
| 12 | 30 | 3.94 | 3.12 | 38.67 |
| 13 | 27 | 3.76 | 3.27 | 14.98 |
| 14 | 17 | 4.83 | 3.82 | 55.49 |
| 15 | 43 | 3.32 | 2.89 | 14.87 |

Test group II: Treated with Open Flap Debridement (OFD) + EDTA + Enamel matrix derivative (EMD) + Bioactive calcium phosphosilicate graft putty

| PATIENT | RANDOMIZATION | BASELINE | 6 MONTHS | PERCENTAGE |
|---------|---------------|----------|----------|------------|
| NUMBER | SERIAL NO. | | | BONE FILL |
| 1 | 23 | 3.24 | 2.18 | 48.62 |
| 2 | 33 | 4.91 | 3.73 | 68.1 |
| 3 | 42 | 3.44 | 2.16 | 59.25 |
| 4 | 2 | 3.72 | 2.53 | 47.03 |
| 5 | 39 | 6.12 | 5.17 | 43.77 |
| 6 | 16 | 4.83 | 3.98 | 42.92 |
| 7 | 5 | 5.84 | 4.24 | 71.42 |
| 8 | 45 | 3.78 | 2.89 | 47.08 |
| 9 | 8 | 4.22 | 2.98 | 62.62 |
| 10 | 32 | 3.82 | 2.77 | 59.32 |
| 11 | 12 | 7.52 | 6.51 | 54.74 |
| 12 | 36 | 4.41 | 3.68 | 43.45 |
| 13 | 26 | 3.82 | 2.63 | 73 |
| 14 | 18 | 4.13 | 2.71 | 83.04 |
| 15 | 7 | 3.76 | 2.53 | 48.61 |